There is a pressing need to develop rapid yet accurate screening assays for the identification of genotoxic liability and for early hazard assessment in drug discovery. The GADD45a-GFP human cell-based genotoxicity assay (GreenScreen HC) has been reformatted to test 12 compounds per 96-well microplate in a higher throughput, automated screening mode and the protocol applied to the analysis of 1266 diverse, pharmacologically active compounds. Testing from a fixed starting concentration of 100 μM and over 3 serial dilutions, the hit rates for genotoxicity (7.3%) and cytotoxicity (33%) endpoints of the assay have been determined in a much wider chemical space than previously reported. The degree of interference from color, autofluorescence, and low solubility has also been assessed. The assay results have been compared to an in silico approach to genotoxicity assessment using Derek for Windows software. Where carcinogenicity data were available, GreenScreen HC demonstrated a higher specificity than in silico methods while identifying genotoxic species that were not highlighted for genotoxic liability in structure-activity relationship software. Higher throughput screening from a fixed, low concentration reduces sensitivity to less potent genotoxins, but the maintenance of the previously reported high specificity is essential in early hazard assessment where misclassification can lead to the needless rejection of potentially useful compounds in drug development. (Journal of Biomolecular Screening 2009:16-30) 
INTRODUCTION

G
ENOTOXICITY IS OF SIGNIFICANT CONCERN in drug development. Genotoxic liability, identified by current in vitro tests, is present in as many as a third of compounds reaching preclinical regulatory evaluation, and about 12% of drug candidates are lost due to genotoxicity safety concerns. 1 Due to the complexity and high cost of long-term animal studies, early judgments about a compound's genotoxicity are made on the basis of results from a battery of regulatory tests. 2 Currently, 3 tests are required, which include a Salmonella bacterial reversion assay (Ames) , an in vitro assessment of chromosomal damage in mammalian cells (metaphase chromosome aberration test or in vitro micronucleus test) or an in vitro mouse lymphoma L5178Y thymidine kinase mutation assay (MLA), and an in vivo assessment of chromosome damage using rodent hematopoietic cells (International Conference on Harmonisation [ICH] guideline S2(B)). An additional in vivo assessment is required when there are positive in vitro data. In revisions to the ICH guidelines (due in late 2008, S2(R1)), there is a new option for regulatory submissions in which the bacterial mutation assay is the only in vitro test performed, but 2 in vivo endpoints are required (see appendix). 3 This approach is effective in identifying genotoxic rodent carcinogens, but it is expensive, and so full regulatory genotoxicity testing is carried out only on 2 or 3 candidate compounds selected for development in any given program.
The expense arises because the regulatory assays require gram quantities of compound and have low compound throughput, taking days to several weeks to complete by skilled personnel. The cost of maintaining a single compound in drug development programs increases rapidly from lead compound identification ($2000) , to lead compound optimization and the initiation of ADMET ($50,000), to preclinical development, bulk synthesis, and detailed ADMET ($2.5 million). 4 The accumulated costs for the loss of a candidate variously have been quoted between $4 and $10 million. The high cost of failure also reflects wasted resources that could otherwise have been channeled into programs to modify chemistry or speed up the development of other more promising candidates. Thus, there is a need for rapid and high-throughput assays for the early identification of a compound's genotoxic potential.
Genotoxicity screening assays also need to be highly accurate. Recently, it has been recognized that there are major problems with the interpretation of data arising from the regulatory battery of in vitro genotoxicity tests. 5 This problem is 2-fold: relatively low sensitivity from the Ames test leading to falsely negative predictions of in vivo hazard and low specificity from the in vitro mammalian assays leading to falsely positive predictions of in vivo hazard. Ames "false negatives" arise because prokaryotes give negative results for compounds that specifically interact with eukaryotic target structures such as chromatin DNA and the different proteins involved in DNA metabolism or chromosome segregation. False-positive predictions from the in vitro mammalian tests are less easy to explain but in some cases arise because of the highly toxic and physiologically unattainable doses applied to detect some bona fide genotoxic carcinogens. In these cases, increased rates of DNA mutation or rearrangement may be associated with apoptosis, endonuclease release from lysosomes, or adverse pH or osmolarity. As a consequence of these high levels of false prediction, compounds negative in Ames and positive in an in vitro mammalian assay ("unique positives") are often carried forward for further investigation into mechanisms of action, involving additional genotoxicity studies in animals to ensure a compound's safety-or the needless rejection of an otherwise promising drug candidate.
Over the past few years, higher throughput versions of in vitro genotoxicity assays have been developed with the aim of reducing the time taken to obtain preliminary data, the amount of test compound required, and the labor cost per compound. Miniaturization also has the advantage of making assays amenable to automation, enhancing both reproducibility and scoring objectivity and standardizing data handling.
Ames II, a fluctuation test for bacterial mutagenicity, uses reduced numbers of tester strains (i.e., TA98 and TAMix [TA7001-7006]) and has been shown to be an effective screening alternative to the more labor-intensive Ames test, demonstrating high concordance with the parent assay using selected compounds. 6 However, the low frequency of mutation events means that a minimum of three 384-well microplates are required per compound tested. Other prokaryotic high-throughput microplate assays have been developed, primarily as predictors for Ames. These include the SOS umuC chromotest 7, 8 and SOS response bioluminescence assay Vitotox™, 9 both based on genetically modified Salmonella strains and the SOS lux bioluminescence assay in Escherichia coli. 10 The SOS prokaryotic assays have, however, found only limited use in pharmaceutical screening, and applications have recently focused on environmental monitoring. Recently, a bioluminescent version of the Ames assay has been developed by Aubrecht et al. 1 using 2 tester strains genetically modified to express a lux (CDABE) operon from Xenorhabdus luminescens. This allows the collection of data from higher plating densities, with concomitant reduction in the use of plasticware. Evaluation with 105 compounds in 24-well plates has shown the assay to be highly concordant with the standard Salmonella plate incorporation assay.
High-throughput genotoxicity assays based on yeast strains exploit the twin advantages of using microorganisms such as robustness, ease of cell culture, and speed of growth, coupled with eukaryotic cells that are more relevant for risk assessment in higher organisms. The DEL assay developed by Hontzeas et al. 11 uses genetically modified Saccharomyces cerevisiae in a histidine-mediated deletion/reversion assay and has been successfully scaled to 96-and 384-well microplate formats. The GreenScreen GC assay from Gentronix Ltd. uses genetically modified S. cerevisiae that express a yeast-enhanced green fluorescent protein (GFP) as a reporter for induction of the RAD54 DNA damage repair gene. 12 The GreenScreen GC assay tests 4 compounds per 96-well plate. Fluorescence induction is the endpoint for genotoxicity assessment, whereas optical absorbance is used as a measure of cell proliferation for the simultaneous assessment of cytotoxicity. A report on validation results from 305 compounds demonstrated both high specificity and sensitivity in the identification of rodent carcinogens when used in combination with the Ames or surrogate assay, 13 and a study of 2698 compounds from Johnson & Johnson's compound collections demonstrated its value in high-throughput screening (HTS). 14 Miniaturizing the regulatory in vitro mammalian tests presents a greater challenge due to the fragility of the cell lines, labor-intensive multistep protocols, and requirement for manual and often more subjective scoring. Streamlining the sample preparation and cell exposure steps of various protocols has, however, successfully reduced processing time. A higher throughput in vitro micronucleus assay using mouse lymphoma L5178Y cells has been developed in which automated scoring of micronuclei and cytotoxicity is achieved by cell-staining approaches with analysis by flow cytometer. 15 The protocol was shown to be transferable between laboratories, but the number of validation compounds and the diversity of their chemistry are currently limited. There is also a routinely used microplate format for the mammalian thymidine kinse mutation assay (MLA), although this still requires many weeks for dose setting and the selection of revertants for counting. 16 A modified 96-well plate version of the Comet assay has been reported to increase throughput and reduce compound requirement. 17 Assessment of viability via a luminescent adenosine triphosphate (ATP) assay allows selection of exposure conditions in the desired range of cytotoxicity to be used in slide preparation, and this effectively doubles the throughput of the standard method.
Although all these genotoxicity screening approaches may act as an effective filter at an early stage of drug development and give a preview of a likely positive result in one or other of the regulatory genotoxicity assays, they do not address the problems of low sensitivity in prokaryotic assays or the low specificity of in vitro mammalian assays.
Recently, a new genotoxicity assay has been described using a human lymphoblastoid TK6 cell line. 18 The GreenScreen HC assay (hereafter referred to as GreenScreen) uses a genetically modified cell line incorporating a GFP reporter based on the proper regulation of the human GADD45a (growth arrest and DNA damage) gene. GADD45a mediates the adaptive response to genotoxic stress, and the patented GFP fluorescence reporter includes p53 regulatory elements. The justification for the selection of a GADD45a transcription-mediated reporter has been described by Hastwell et al. 18 Initial validation work included an analysis of 75 well-characterized genotoxic and nongenotoxic compounds with diverse mechanisms of action and demonstrated that the assay responds positively to all classes of genotoxic damage, with uniquely both high specificity and sensitivity. The GreenScreen assay protocol tests 4 compounds per 96-well plate, each tested over 9 serial dilutions. Compounds in the published study were tested to the ICH guideline of 10 mM or to the limit of solubility or cytotoxicity, with at least 4 replicates to corroborate results.
The aim of this study was to reformat the GreenScreen assay into a much higher throughput format more suited to robotic liquid-handling automation and allow the testing of 12 compounds per 96-well microplate, each over only 3 serial dilutions and testing each once. Compounds were tested from a fixed concentration of 100 μM, consistent with the maximum achievable in the assay for library collection compounds stored at 10 mM in 100% DMSO, due to the limitations of 1% v/v DMSO tolerance in the assay. Analysis of a much larger set of 1266 compounds comprising the Sigma-Aldrich Library of Pharmacologically Active Compounds (LOPAC) collection has allowed quantification of the typical hit rates for the GreenScreen assay when used in an HTS mode in a wider pharmaceutical chemical space. In addition, the effect of restricting the test concentration range on the reported sensitivity and specificity of the GreenScreen assay has been assessed. Substantially expanding the range of chemistries analyzed with the GreenScreen assay has enabled greater characterization of the types of compound the assay responds to and the limitations imposed by test compounds' solubility and autofluorescence. Finally, the GreenScreen assay results have been compared to an in silico approach to genotoxic assessment using alerts and predictions for mutagenicity, chromosome damage, and carcinogenicity using Derek for Windows software.
MATERIALS AND METHODS
Cell lines and plasmids
The TK6 cell line was obtained from the European Collection of Cell Cultures. The wild-type TK6 cell line was selected as it is homozygous at the p53 locus, whereas most other mammalian cells contain at least 1 mutant copy. p53, often referred to as the "guardian of the genome," is required for the proper regulation of both the GADD45a gene and the response to genome damage. TK6 is also a suspension cell line that is therefore more suited to automated liquid handling.
Genetic modification of the parent strain to produce the reporter strain (GenM-T01) by fusing the GFP gene to the GADD45a promoter and other regulatory elements has been described elsewhere. 18 A second control strain (GenM-C01) contained an out-of-frame EGFP gene, such that a functional and fluorescent GFP protein is not produced. This strain was used to allow effective correction for any test compound's autofluorescence that may otherwise give a false indication of GFP induction in the reporter strain. Cells were maintained in RPMI-1640 medium (Invitrogen Corp., Carlsbad, CA) supplemented with 10% v/v heat-inactivated horse serum (Lonza, Wokingham, UK) and 10 mM sodium pyruvate (Invitrogen) at 37 °C, 5% CO 2 , and 95% humidity, passaging every 1 to 4 days. The plasmids were stably maintained in TK6 by addition of 200 μg/mL hygromycin B (Invitrogen) to the culture medium.
For the assay, cells were taken from stocks that had reached between 5 × 10 5 and 1.2 × 10 6 cells/mL. Each assay microplate required a 5-mL suspension of each cell line at a density of 2 × 10 6 cells/mL. Cells were harvested from an appropriate volume of culture by centrifugation at 340 relative centrifugal force (RCF), washed clear of RPMI medium with phosphatebuffered saline, and resuspended in assay medium containing 20% v/v of a serum-free medium supplement (Gentronix Ltd., Manchester, UK). The serum-free supplement contains water, HEPES buffer, and trace amounts of synthetic, purified proteins normally present in serum. The use of serum-free supplement in place of horse serum for the microplate assay is one key improvement in the protocol over that previously reported. 18 The subsequent reduction of autofluorescence in the medium produces greater clarity in the quantification of GFP fluorescence.
Compound preparation
The LOPAC test compounds were provided as frozen 250-μL aliquots of 10-mM solutions in DMSO. The aliquot was thawed and vortexed, and 10 μL of stock solution was added to 490 μL of sterile, distilled water. The resulting solution was diluted 2-fold when combined with cell culture on the microplate, producing a top concentration of 100 μM in 1% v/v DMSO. If the compound required a second test due to high cytotoxicity, a second 10-μL aliquot was aspirated from the stock solution and diluted appropriately with 100% DMSO. Then, 10 μL of the resulting solution was used for the aqueous dilution.
The average molecular weight of compounds in the LOPAC collection is 339 Da with a range from 42.4 to 1505 Da. Hence, compound consumption in the GreenScreen assay is low. Based on the average molecular weight, the actual amount of material used per test is approximately 34 μg.
Microplate preparation
Assays were carried out in 96-well, black, clear-bottomed, polystyrene, sterile microplates (Matrix ScreenMates, cat. no. 4929, ThermoFisher Scientific, Wilmslow, UK). The microplates were prepared using a liquid-handling robot (Precision XS, Biotek, Winooski, VT), which combines an 8-channel reagent dispenser, an 8-channel pipettor, and a combined single-channel pipettor/ dispenser.
The microplate layout is shown in Figure 1 and was prepared in the following way: 75 μL of diluent (2% v/v DMSO) was added to the microplate in columns 2, 3, 5, 6, 8, 9, 10, and 12. Then, 150 μL of each of 12 test compounds was transferred from samples tubes to the microplate in columns 1, 4, and 7, as dictated in Figure 1 . High (100 μg/mL) and low (20 μg/mL) controls of a standard genotoxicant, methyl methanesulfonate (MMS), were added to column 11. Working column-wise left to right, the 12 test compounds were serially diluted into the 2 proceeding columns, transferring 75 μL in each step and thus realizing 50:50 serial dilutions. In column 12, 75 μL of diluent was added to wells A12 to D12, and 75 μL of assay media alone was added to wells E12 to H12. Comparative measure of absorbance between the assay media and diluent provided a check for the absence of media contamination.
Both cell strains were added simultaneously with an 8-channel pipettor using a split reagent trough with 2 compartments containing the respective strains. Plates were covered with a breathable sealing membrane (Breathe-Easy, Diversified Biotech, Boston, MA), shaken for 10 s to combine the cell culture and test compounds, and then statically incubated at 37 °C, 5% CO 2 , and 95% humidity.
Microplate reading
At both 24-and 48-h time points, the microplates were shaken for 20 s to resuspend the cells and the sealing membranes removed. The plates were read for optical absorbance (620 nm) to quantify cell density and fluorescence (excitation 485 nm, emission 535 nm) to quantity GFP expression. Measurements were made with a Tecan Ultra microplate reader (Tecan, Theale, UK) and raw data exported to an Excel template developed in-house.
Data analysis
Cytotoxicity was assessed by the percentage reduction in cell proliferation (relative cell density) compared with that achieved in the untreated controls. It is important to note that this is not a measure of cell viability or death. If the relative cell density fell below 80% at 1 test concentration, the compound was deemed cytotoxic (+) and, if extended over 2 or 3 concentrations, strongly cytotoxic (+ +). Otherwise, the compound was deemed negative for cytotoxicity. A relative cell density of less than 30% represents the case where the cells have not proliferated, and below this figure, cell lysis makes data uninterpretable. The fluorescence value was divided by cell density to give a relative fluorescence per cell or "brightness" value. Fluorescence induction due to GFP expression was determined by first subtracting brightness signal of the control strain from that of the test strain to correct for any autofluorescence of the test compound and then compared to equivalent measurements from the untreated controls. If induction of GFP fluorescence exceeded 50% (i.e., a threshold of 1.5) at 1 test concentration, the compound was deemed genotoxic (+) and, if extended over 2 or 3 concentrations, strongly genotoxic (+ +). Otherwise, the compound was deemed negative for genotoxicity.
The bespoke software template produced both graphical and semi-quantitative data automatically, giving a call for cytotoxicity and genotoxicity and lowest effective concentration (LEC). The LEC is the lowest test concentration at which the measurement of cell density or GFP induction crosses the relevant significance threshold. Significance thresholds were set at >3 times the standard deviation in the response for nontoxic compounds. Test compounds are deemed positive for cytotoxicity or genotoxicity if a positive response is observed at either 24 or 48 h, and when results differ between 24 and 48 h, the strongest response is that reported, that is, (+ +) > (+) > (-).
The high-concentration MMS control should produce a greater than 2-fold induction in GFP fluorescence, reduce the relative cell density to less than 80%, and give a dose-dependent response in comparison to the low-concentration MMS control.
Examples of graphical results, including the response from both cell strains and the significance thresholds, are shown in Figure 2 , in which all 4 compounds were taken from the same microplate.
In silico data analysis
In silico analysis was performed using Derek for Windows (DfW; Lhasa Ltd., Leeds, UK; Version 10.0.2 processing the structure data file [SDF] supplied by Sigma-Aldrich). Both bacteria and mammal species groups were selected to enable wide coverage of mutagenicity, carcinogenicity, and chromosome damage endpoints. Nine structures were unresolvable principally due to valency conflicts in the SDF, and structures were redrawn and reprocessed, with the exception of ceramide, a lipid molecule composed of sphingosine and a fatty acid with various substituents rather than a unique structure. >20%. This effect was caused either by compound color or by precipitation from solution upon incubation with assay media, and both can reduce sensitivity for cytotoxicity assessment by optical density. However, only 5 compounds (0.4%) formed significant precipitates at the concentrations tested. Of the compounds, 115 (9.1%) were visibly colored in solutionprincipally pale yellow-but only 1 compound, Reactive Blue 2, interfered with the measurement of optical absorbance to the extent that it could not be analyzed in the standard procedure, producing a perceived relative cell density greater than 400%. However, interference in the optical absorbance measurement was completely removed by switching from 620 nm to an alternative available filter at 492 nm. All other compound results on the same microplate were unaffected because the "absorbance" of light by the presence of cells is largely independent of wavelength. For 275 compounds (21.8%), the presence of the test compound increased the fluorescence of the control cell wells by >20% due to the compound's autofluorescence. However, the use of the nonfluorescent control strain allowed for efficient correction of the GFP fluorescence in the test strain in almost all cases. Only 5 compounds (0.4%) demonstrated autofluorescence to the extent that they were unassayable for genotoxicity (4-amino-1,8-naphthalimide, ellipticine, idarubicin, quinacrine dihydrochloride, and sepiapterin). These compounds are highly conjugated with 2 to 4 conjoined unsaturated-ring structures.
RESULTS AND DISCUSSION
Physicochemical properties of the compounds
All assays with optical endpoints suffer from interference when analyzing colored, fluorescent, or insoluble compounds. However, in this study of a collection of compounds with a diverse range of physicochemical properties and testing from a fixed concentration of 100 μM, only a very small percentage could not be tested in GreenScreen due to insolubility or autofluorescence.
Screening hit rates for genotoxicity and cytotoxicity Table 1 summarizes the overall results for genotoxicity and cytotoxicity for all compounds screened. Of the compounds, 92 (7.3%) were positive for genotoxicity, and this prevalence for genotoxicity is similar to other recent screening studies of pharmacologically active compounds.
14 In total, 419 compounds (33%) caused a statistically significant reduction in cell density at or below 100 μM and were deemed positive for cytotoxicity. Comparing the 2 endpoints, 20% of cytotoxic compounds were also genotoxic, whereas 89% of genotoxic compounds were also cytotoxic. It is therefore clear that cytotoxicity alone does not produce a genotoxic response in the assay. Sixty-five compounds (5.1%) were tested a second time from a lower starting concentration as cytotoxicity had reduced the relative cell density to below 30% at 1 or more test concentrations.
In total, 111 compounds (8.8%) were only positive for cytotoxicity at the 48-h time point. This reflects the increasing cytotoxicity to the cells with the prolonged incubation with the test compound during which time the cell density of the untreated controls continues to increase. Five compounds (0.4%) were positive at 24 h and negative by 48 h. This may be due to the instability of the compound or its metabolites or short-lived cytotoxic effects from which the cells recover when incubated for a further 24 h.
Twenty-four compounds (1.9%) were only positive for genotoxicity at the 48-h time point. This reflects both the increasing toxicity to the cells with prolonged incubation with the test compound as well as the mechanistic consideration that the detection of genotoxins that cause chromosome missegregation requires that cells attempt mitosis before an error is detected by the cell. Thus, genotoxic responses from such compounds are more evident at 48 h. Fifteen compounds (1.2%) were positive at 24 h and negative at 48 h. Again, this may be due to the test compound's instability or short-lived genotoxic effects.
The average LECs were 17.1 μg/mL and 18.0 μg/mL for genotoxicity and cytotoxicity, respectively. This reflects the link between DNA damage and the cell cycle: failures in DNA replication or chromosome capture lead to cyclin-dependent kinase delay in mitosis and reduction or cessation in growth. Table 2 summarizes the LECs for positive genotoxicity and cytotoxicity results. More than 45% of compounds that gave positive results were toxicologically active down to the lowest concentration tested in the first analysis (25 μM). Thus, testing from 100 μM effectively captured the toxic concentration range of a high proportion of substances in the LOPAC library. In silico data analysis
Derek for Windows alerts for chromosome damage, carcinogenicity, and/or mutagenicity were given for 427 compounds (33.7%). Fifty-four different alerts were recorded, and the alerts in the subset of 92 compounds that were positive for genotoxicity in GreenScreen are detailed in Table 3 . The nature and number of the alerts reflect the diverse chemical structures present in the LOPAC collection and the diversity of chemistry that can produce a positive response in GreenScreen. A separate analysis of the collection using the previous DfW software (Version 9.0.0) highlighted a large number of carcinogenicity alerts for aromatic amines (209 compounds), secondary amines (181 compounds), and aromatic amides (58 compounds). These less specific alerts have been deactivated in the later version of the software and are replaced in part by 4 new alerts describing the genotoxic carcinogenicity of aromatic amines and amides. Eight compounds were highlighted in this new category.
The DfW predictions obtained for mutagenicity, chromosome damage, and carcinogenicity were graded probable, plausible, and equivocal. Probable indicates that there is at least 1 strong argument that the proposition is true and there are no arguments against it. Plausible indicates that the weight of evidence supports the proposition. Equivocal indicates that there is an equal weight of evidence for and against the proposition. In the context of the results obtained in this study, probable means that the query structure has matched an alert, and a supporting example with positive Figure 3 . Reassuringly, in each case, the percentage prevalence of genotoxicity predictions in the subset of compounds that were positive in the GreenScreen assay is higher than that in the compound collection as a whole, especially for plausible chromosome damage predictions where there was a 2-fold difference. However, this observation carries the caveat that the GreenScreen positives represent just 7.3% of the 1266 compounds in the collection.
There is a much higher prevalence (34%) for a positive result in 1 or more of the in silico genotoxicity endpoints than the 7.3% of compounds positive in GreenScreen. This large discrepancy may be due to overrepresentation of certain chemical classes. For example, 58% of compounds in the LOPAC collection are active in neurotransmission. Second, not all compounds within an alerting class will be genotoxic and/or carcinogenic (i.e., DfW predictions were primarily plausible rather than probable or certain). Furthermore, the GreenScreen assay was conducted without exogenous metabolic activation, whereas DfW contains data derived from many assays that routinely incorporate metabolizing substrates such as S9 fraction. Much of the historical data for carcinogenicity were derived using animals exposed to chronic sublethal doses, leading to increased cell damage and death. In turn, increased cellular replacement requires enhanced rates of DNA replication, and this increases the chance of DNA mutation and thus risk of cancer. Developing structure-activity relationship (SAR) rules for molecules that never reach such chronic doses in man is hence likely to overestimate hazard. 19 Significantly, only 46 of the 92 compounds (50%) that were positive for genotoxicity in GreenScreen produced genotoxicity alerts in DfW, despite the reliability of a GreenScreen-positive result (see Table 4 ). 18 Thus, GreenScreen identifies many nonalerting genotoxic compounds and complements the in silico approach in a first-line screening strategy. A survey of the chemical structures of DfW nonalerting GreenScreen-positive compounds revealed that more than half contained tertiary aliphatic amine groups that commonly occur in polyheterocyclic compounds, although they are less chemically reactive functional groups. Such compounds are positive in other genetic toxicity assays. Eight contained catechol or flavone substructures, common motifs in compounds that are genotoxic in a diverse range of assays. 20 Three were complex natural products for which it is difficult to assign nonspecific structural motifs for genotoxicity alerts. These were dihydroouabain and 2 known aneugenic compounds, taxol 21 and podophyllotoxin.
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Prediction of carcinogenesis
The aim of most in vitro genotoxicity assays is to predict the potential for genotoxicity or carcinogenicity in vivo and then by extrapolation from rodents to man. Several freely accessible databases were consulted to collate carcinogenicity data from rodent studies. To manually search these databases in an efficient way, we sourced the CAS registry number of each compound from the Sigma-Aldrich catalog. CAS numbers were established for 1112 compounds (87.8%) in the collection, and these were used to interrogate the toxicity databases listed.
Only 97 compounds (7.7%) had carcinogenicity data, positive or negative, in the toxicity databases consulted, and this is not surprising because many are development drugs that have not progressed as far as detailed characterization of genotoxicity. In this respect, LOPAC reflects the routine case for a screener. However, 50 compounds had positive carcinogenesis data in 1 or more species. This high proportion of positive data is a result of the fact that cancer studies are more likely to be performed when risk has been suggested by in vitro studies or conceived exposure. Of these 50 compounds, GreenScreen alerted for 20%, whereas DfW alerted for 56% combining all genotoxicity-related alerts and for 42% considering only carcinogenicity alerts. The lower sensitivity of GreenScreen will be partly a result of screening from a fixed, low concentration (text continues on p. 28) of 100 μM compared with the ICH recommended limit of 10 mM (proposed to be reduced to 1 mM 3 ) and testing over a narrow concentration range. Only 14 compounds were consistently positive for carcinogenicity across both sexes and species and thus were more likely to be directly acting by a genotoxic mechanism. No attempt was made to discriminate between genotoxic and nongenotoxic mechanisms of carcinogenesis because this is not a trivial analysis, and literature data are limited for these particular compounds.
The CPDB database contains information on carcinogenic potency in the form of TD 50 data for 34 of the 50 carcinogens. TD 50 is the dose in mg/kg body weight/day for life to induce tumors in half of test animals that would have remained tumor free at zero dose. All 8 of the compounds from this subset, which were also positive in the GreenScreen assay, had TD 50 values less than 2% of that of the least potent compound, Gabapentin (TD 50 = 5850). Hence, in this screening format, the GreenScreen assay detects the most potent carcinogens.
Forty-seven compounds were negative in all cancer studies, and GreenScreen correctly identified 46 (98%) of these, whereas DfW was correctly nonalerting for only 66% combining all genotoxicity-related alerts and for 77% considering only carcinogenicity alerts. Methotrexate, the single misclassified noncarcinogen, interferes with DNA precursor supply and is also reported to be positive in several other in vitro and in vivo genotoxicity assays.
Therefore, the high specificity of the GreenScreen assay, previously reported by Hastwell et al., 18 was maintained in this HTS protocol. High specificity is a key requirement for early screening as it prevents incorrect hazard assessment and unnecessary loss of potentially valuable compounds or delays in their development.
Characteristics of GreenScreen HC positives
The 92 compounds that were positive for genotoxicity in GreenScreen are listed in Table 4 along with the corresponding evaluation of cytotoxicity, LECs, and their principal pharmacological activity. It is both striking and unsurprising that 28 of the 92 compounds are antineoplastic agents acting by a variety of DNA corrupting mechanisms, including alkylation, antimetabolite, antimitotic, or inhibition of topoisomerases. All but 5 of this subset of compounds were strongly positive in GreenScreen, and they include familiar genotoxic pharmaceuticals such as chlorambucil, 5-azacytidine, 5-fluorouracil, taxol, and etoposide. This study has highlighted the detection of in vitro genotoxic effects of a group of tyrosine phosphorylation inhibitors. These compounds, known as tyrphostins, were discovered in the 1980s to have potential for use as novel, less cytotoxic chemotherapeutic agents. These comprise a wide range of small molecules that block the activity of a narrow spectrum of protein tyrosine kinases (PTKs) that are involved in metabolic signaling and cell proliferation. 23 In the disease state, the activity of PTK is often enhanced, leading in some cases to persistent stimulation and abnormal, unchecked cell proliferation. An examination of the structure of the tyrphostins reveals that in this compound collection, GreenScreen discriminates between selective PTK inhibitors and nonselective ones that inhibit other kinases and ATP requiring enzymes (see Fig. 4 ). Nine nonselective tyrphostins (numbers 1, 23, 47, 51, A9, AG34, AG112, AG126, AG808) were all negative in GreenScreen. In contrast, 6 selective tyrphostins (AG490, AG494, AG528, AG555, AG698, and AG835) were all positive in GreenScreen, and 2 selective tyrphostins (AG527 and AG538) and 1 highly selective quinazoline tyrphostin (AG1478) gave GFP induction values between 1.37 and 1.46, close to the threshold for a positive result. A further compound, tyrphostin AG537 with a dimeric structure of 2 linked benzenemalonitrile backbones, was negative in the assay. Many tyrphostins are thought to have more than one mechanism of action, including indirectly inducing DNA damage by blocking topoisomerase I or II. 24 There are many pairs of closely related structural and stereoisomers in the LOPAC collection. The majority gave the same GreenScreen results for cytotoxicity and genotoxicity despite the highly chiral nature of the cellular environment. Notable stereoisomeric exceptions that gave conflicting cytotoxicity results included cis-and trans-isomers of azetidine-2,4-dicarboxylic acid (+ and -, respectively), bestatin HCl and epibestatin HCl (+ + and -, respectively), propafenone and (S)-(-)-propafenone hydrochlorides (-and +, respectively), rauwolscine and yohimbine hydrochlorides (+ and -, respectively), and quinidine and quinine sulfates (+ + and -, respectively).
One group of closely related structural isomers giving contrasting genotoxicity results were the 6 bioflavonoids. At the concentration tested, apigenin, myricetin, daidzein, luteolin, and quercetin were all negative, whereas genistein was positive in GreenScreen. This is consistent with the observation that genistein shows the highest clastogenic activity of the tested bioflavonoids. 20 It is also a topoisomerase II poison and an early PTK inhibitor. 
Conclusions
The GreenScreen HC assay has been developed into a higher throughput format than screening versions of most other in vitro genotoxicity assays, and the analysis of 240 compounds per day (20 microplates) is readily achievable. Compound consumption is very low, equivalent to just 10 μL of a typical DMSO library stock solution. Testing from 100 μM over 3 serial dilutions captured the toxic range of the library of pharmacologically active compounds without significant interference from color, autofluorescence, or low solubility. It is worth noting that even though this concentration is 100 times lower than the current (ICH) guideline, it is still very high in pharmacological terms.
Where data were available from carcinogenicity studies, GreenScreen demonstrated a higher specificity than an in silico method and also identified genotoxic species that were not highlighted for genotoxic liability in SAR software despite the reliability of a positive GreenScreen result. Higher throughput screening from a fixed, low concentration reduced sensitivity; however, the maintenance of the previously reported high specificity is essential in early hazard assessment, where misclassification can lead to the needless rejection of potentially useful compounds. 18 For screening purposes, the identification of potent genotoxins is probably sufficient.
Understanding the toxicity data and classifying risk with reference to chemical structure or by examination of the diverse and often conflicting published test data are complex and laborious. However, in a real sense, compound screeners do not have that problem as they will generally have access only to "screening data," used for early hazard assessment as part of a broader profiling exercise in which other factors such as therapeutic indication will have an influence in attrition. The analysis in this work has shown that screening detected the most potent carcinogens and compounds that either damage the genome or disrupt DNA synthesis and metabolism.
The assay has the potential to be scaled down to 384-well microplates to further increase throughput, although moving to 1536 wells would need more specialized adaptation due to the potential for evaporative loss of liquids and the difficulties of accurately measuring cellular fluorescence in small volumes of cell culture. However, preliminary results in our laboratory have shown proof of principle for a luminescence reporter gene based on GADD45a for which sensitive detection at low volume should be more accessible, and this shows promise for another future step change in throughput for genotoxicity screening.
